Catherine Wood, founder of ARK Investment Management, acquired 1,623,868 shares of CRISPR Therapeutics AG at $51.17 each, raising her firm's total holdings to 9,122,493 shares, or 4.24% of the portfolio. This move underscores her confidence in the biotechnology sector and CRISPR's gene-editing technologies, despite the company's current overvaluation. CRISPR Therapeutics, valued at $4.19 billion, is a leader in gene editing, with a focus on addressing significant medical needs through innovative therapeutics.